newsfilter
← Latest News
Business Wire·

Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

XERS
  • Xeris Biopharma Holdings announced the USPTO issued a Notice of Allowance for its subsidiary Xeris Pharmaceuticals Inc.'s U.S. patent application covering the XP-8121 formulation.
  • The allowed claims are specific to the XP-8121 formulation, with the patent expected to issue following standard administrative steps.
  • Xeris continues to pursue additional U.S. & international IP protection layers in the levothyroxine (LT4) technology space.
  • XP-8121 is an investigational, ready-to-use liquid levothyroxine sodium designed for once-weekly subcutaneous injection using the XeriSol® platform.
  • The subcutaneous approach aims to address oral levothyroxine limitations, including variable absorption, drug/food interactions, & inconsistent therapeutic effects.
  • CEO John Shannon stated this patent is a key milestone for strengthening IP protection around the hypothyroidism pipeline program.
  • Xeris currently markets Recorlev® (Cushing's syndrome), Gvoke® (severe hypoglycemia), & Keveyis® (primary periodic paralysis).
  • The company is headquartered in Chicago, IL, with XP-8121 as a Phase 3-ready candidate in its development pipeline.